LY2140023: Clinical Trials

7 trials of LY2140023, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 2 terminated. 7 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 27Completed 5, Terminated 2
Phase 31Terminated 1

Follow LY2140023: new trials by email Literature Review of LY2140023 trials Research Report on LY2140023

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Long-Term, Open-Label, Study on Schizophrenia
LY2140023, Olanzapine, Aripiprazole - Schizophrenia
Phase 2 / Phase 3TerminatedDenovo Biopharma LLC5602010-06-012026-09-14
A Study in Schizophrenic Patients
LY2140023, Placebo - Schizophrenia
Phase 2TerminatedDenovo Biopharma LLC822010-05-012021-09-14
A Comparator Study of LY2140023 Versus Placebo in Schizophrenia Patients
Risperidone, Placebo, LY2140023 - Schizophrenia
Phase 2CompletedDenovo Biopharma LLC11342010-03-012026-09-14
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
LY2140023, Placebo, Standard of Care - Schizophrenia
Phase 2CompletedDenovo Biopharma LLC1672010-01-012022-09-07
A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients
LY2140023, aripiprazole, olanzapine - Schizophrenia
Phase 2CompletedDenovo Biopharma LLC2612009-03-012022-11-08
A Study for Participants With Schizophrenia
LY2140023, Olanzapine, Placebo - Schizophrenia
Phase 2CompletedDenovo Biopharma LLC6692007-09-012026-09-14
Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo
LY2140023, olanzapine, placebo - Schizophrenia
Phase 2CompletedDenovo Biopharma LLC1952005-08-232021-08-20

Conditions studied

Schizophrenia (7)

Sponsors

Denovo Biopharma LLC (7)

Countries

Russia (5)  ·  United States (4)  ·  Croatia (3)  ·  Mexico (3)  ·  Germany (2)  ·  Japan (2)  ·  South Korea (2)  ·  Taiwan (2)  ·  Argentina (1)  ·  Austria (1)  ·  Israel (1)  ·  Italy (1)  ·  Portugal (1)  ·  Puerto Rico (1)  ·  Romania (1)

Results publications

PMID 25890643, PMID 25539791